|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Since colon cancers are heterogeneously differentiated, we set out to determine if the GRPR gene was mutated as a function of tumor cell differentiation in archived human colon cancers.
|
12720295 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no significant difference in GRPR mRNA expression of primary tumors versus paired metastases.
|
28107508 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, the in vivo results confirmed that the blood clearance of the nanoprobe happened during the first 120 min post-injection of the radiolabeled nanoprobe and also confirmed the targeting ability of that to a gastrin-releasing peptide receptor positive tumor.
|
31519003 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors.
|
10828496 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of the current study was to develop a <sup>55</sup>Co-labeled PET agent based on GRPR antagonist RM26 for visualization of GRPR-expressing tumors.
|
29097932 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, we describe here the first examples of HBPLs being able to address the GRPR as well as the VPAC<sub>1</sub>R and have the potential to - by several mechanisms - improve tumor targeting for several malignancies compared to monospecific peptides.
|
29864700 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gastrin-releasing peptide is a neuropeptide linked to tumor aggressiveness, acting as an autocrine tumor growth factor by binding to its receptor, gastrin-releasing peptide receptor, expressed by many tumors.
|
28351312 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we assessed how the presence of gastrin-releasing peptide receptor (GRPR) and α<sub>v</sub>β<sub>3</sub> integrin together with the morphology of the vascularization reflects the growth behavior of tumors after hyperthermia treatment.
|
28761146 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using PC-3 tumor-bearing xenograft mice, it was observed that the CC trapping, GRPR-targeted agonistic and antagonistic constructs led to an approximately 2-fold increase in tumor retention with a corresponding improvement in most T/NT ratios over 72h.
|
31601697 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Effects of androgen regulation on GRPR expression were initially studied on tumors obtained from our biorepository of xenograft tissues performing reverse transcriptase polymerase chain reaction (RT-PCR) and autoradiography ((125)I-universal-BN).
|
19876914 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant inverse correlations were found for GRPR and increasing Gleason score, PSA value, and tumor size.
|
21739464 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The levels of GRPR expression in the tumor and adjacent normal epithelium of individual patients with SCCHN were correlated (r =.652; P =.001), suggesting that increased GRPR expression is an early event in SCCHN formation.
|
11880476 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell treatment including gastrin-releasing peptide receptor antagonists combined with inhibition of epidermal growth factor receptor resulted in an additive effect on blocking cell proliferation.
|
19115523 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We herein compare the impact of the two methods on the bioavailability and localization of <sup>177</sup>Lu-DOTA-PEG<sub>4</sub>-[Nle<sup>14</sup>]BBN(7-14) analogs in GRPR-positive tumors in mice.
|
28636973 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GRP-R knockdown also up-regulated the expression of tumor suppressor PTEN, the inhibitor of the PI3K/Akt pathway.
|
18753628 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study demonstrates that (64)Cu-DOTA-Aoc-BN(7-14) can be used to detect GRPR-positive tumors by PET imaging.
|
12862428 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings indicate that <sup>68</sup>Ga- or <sup>177</sup>Lu-labeled NeoBOMB1 is a promising radiotracer with excellent tumor uptake and favorable pharmacokinetics for imaging and therapy of GRPR-expressing tumors.
|
27609789 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.
|
9815798 |
1997 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The current study aimed to develop clinically translatable BBN analogue‑based radioligands for positron emission tomography (PET) of GRPR‑positive tumors.
|
25586565 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We sought to evaluate the tumor binding and imaging potential of (177)Lu-AMBA in low GRP-R models of prostate cancer and determine how reduced expression affects (177)Lu-AMBA radiotherapy efficacy.
|
19910427 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In short, this study has revealed superior pharmacokinetics and higher stability for the GRPR-antagonist <sup>111</sup> In-SB9 vs the corresponding agonist <sup>111</sup> In-AMBA consolidating previous evidence that GRPR antagonists are preferable to agonists for tumor imaging and therapy.
|
30963606 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bombesin receptor 2 (BB<sub>2</sub>) and integrin α<sub>v</sub>β<sub>3</sub> receptor are privileged targets for molecular imaging of cancer because of their overexpression in a number of tumor tissues.
|
29587479 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Preliminary in vivo studies of 64Cu-6 in NMRI nu/nu mice, bearing the human prostate tumor PC-3 showed an accumulation of the conjugate in the tumor (2.25 +/- 0.13 SUV, 12.5 min p.i.; 0.94 +/- 0.05 SUV, 55 min p.i.) and allowed a clear visualization of the gastrin-releasing peptide receptor distribution by positron emission tomography (PET).
|
19173600 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice administered a control adenoviral vector encoding the gastrin-releasing peptide receptor did not have tumor localization of [(111)In]-DTPA-D-Phe1-octreotide (<1.6% ID/g), demonstrating specificity of [(111)In]-DTPA-D-Phe1-octreotide for the AdCMVhSSTr2 induced tumor cells.
|
10037188 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GRPR immunohistochemical staining of tumor samples was performed.
|
29123014 |
2018 |